Navigation Links
AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer

cinomas carrying the erlotinib-resistant mutation EGFR L858R/T790M. These in vivo results suggest that AV-412 may exert potent clinical activity against non-small cell lung cancer tumors harboring EGFR L858R or EGFR L858R/T790M mutations.

About AV-412

AV-412 is a next generation oral tyrosine kinase inhibitor of EGFR/HER2 that could potentially treat patients with solid tumors. In preclinical studies, AV-412 has shown excellent activity in various tumor models, has a toxicity profile similar to other molecules in its class, and has shown preclinical activity against tumor cells that are resistant to first-generation tyrosine kinase inhibitors. The targets of AV-412 have been implicated in many significant human cancers including non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer and hormone refractory prostate cancer. AVEO's proprietary Human Response Prediction(TM) Platform offers an opportunity to exploit AV-412's unique characteristics and will provide further insight into potential clinical settings, tumor subtypes and responsive patient populations. AVEO acquired worldwide rights outside of Asia to AV-412 from Mitsubishi Pharma Corporation. For more information on the AV-412 clinical trial, visit www.clinicaltrials.gov and search using the keyword AV-412.

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by Q3-2007 for AV-951, its oral, second-generation VEGF receptor inhibit
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)... Aug. 27, 2015  PinnacleHealth CardioVascular Institute enrolled the first ... the United States in a trial ... stent for blockages in the main artery of the leg. ... and potentially less risk for stent fracture or re-narrowing after ... single-arm, multicenter clinical trial of the BioMimics 3D Stent System ...
(Date:8/27/2015)... 27, 2015 According to ... Research titled "Global Market Study on Urinary Catheters: ... 2021", the urinary catheters market is expected to be valued ... It is anticipated to expand at a CAGR ... Mn by 2021. View full report TOC ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... Mobile Dog Heart Health Tour is heading south to ... health examinations in San Antonio,s McAllister Dog Park. From ... veterinary cardiologists will be performing on site heart screenings ... owners about canine heart disease. (Photo: ...
... Celsis In Vitro, Inc. (Celsis IVT) announced today ... District of Illinois in Chicago has entered a preliminary ... (the Defendants) due to their infringement of U.S. Patent ... California (Nasdaq: LIFE ) is the parent ...
Cached Medicine Technology:Free Dog Heart Checks at McAllister Park 2Free Dog Heart Checks at McAllister Park 3Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 2Celsis IVT Wins Preliminary Injunction Against Life Technologies and CellzDirect in Liverpool™ Patent Infringement Lawsuit 3
(Date:8/27/2015)... ... August 27, 2015 , ... For the first time, ... with the Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. ... takes drink customization to a whole new level. This line of Nutri Ninja ...
(Date:8/27/2015)... ... August 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue ... of 2016. The new facility will be located at US Highway 19 North and Highlands ... on August 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... ... 27, 2015 , ... King Kullen, America’s First Supermarket, is celebrating 85 years ... in 1930 and recognized by the Smithsonian Institute as America’s First Supermarket, King Kullen ... the Cullen & Kennedy families have created a culture of caring while building their ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since ... has grown to having twelve offices in three counties, LA, Orange and San ... Southern California region. Founded by Dr. Richy Agajanian, the Oncology Institute of ...
(Date:8/27/2015)... ... 27, 2015 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that Ms. Esther Sadler-Williams, Global Director Strategic Development and ... Radisson Blu Edwardian Hotel, London Heathrow, on September 9th – 10th, 2015. , ...
Breaking Medicine News(10 mins):Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:King Kullen Honors Their 85 Years of Success this August 2Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Clinical Trial Supply Chain Logistics to be Discussed By Catalent Expert at Upcoming Flypharma Conference 2
... Non-profit organization RAND Corp. has come out with a finding ... who tend to use substance like marijuana, alcohol, and cigarettes ... a younger age, and to have a harder time quitting, ... setting or in groups. ,The results stem from ...
... on the dead skin of visitors' feet is turning into ... // ,Hordes of Turkish spa fish, members of the ... first Fish Reflexology spot at the Underwater World attraction., ... skin are removed by the fish., ,It costs $22 ...
... the scheme 'Assistance for capacity Building', Ministry of ... a maximum //of Rs. 1.50 crores or actual, ... emergency facilities of State Hospitals of towns/cities located ... NHAI, Department of Road Transport and Highways and ...
... Board of Health in a surprise move went back ... change the sex on their birth //certificates, without physically ... seconded by mental health professionals and transgender supporters, who ... discrimination against people who desire to adopt the 'opposite' ...
... A draft report from NHS Institute for Innovation and Improvement ... by GPs and visiting //nurses rather than admitting them in ... a range of conditions regularly seen in Accident and Emergency ... more could be done for reducing the numbers admitted in ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
Cached Medicine News:
Gentle curve facilitates less traumatic removal from eye. Increased length ideal for myopic eyes...
Great for small incisions and excision needs...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
2.5mm...
Medicine Products: